nasdaq sage - Search News

Sage rejects Biogen’s buyout offer

Sage rejects Biogen’s unsolicited bid, but open to other offers

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its board of directors has initiated a process to explore strategic alternatives for the company.

Investing.com on MSN · 8h

Mizuho raises Sage Therapeutics target to $9 on Biogen bid

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on the stock.

Reuters on MSN · 2d

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.

EconoTimes · 2d

Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.

The Business Journals · 3d

Sage rejects Biogen’s buyout offer, but says it's open to deals

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.

3don MSN

Sage Therapeutics shares rise amid strategic review

Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the ...

Nasdaq3d

Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up

SAGE is currently trading at $24.93, up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at $147.98 up 1.21 percent or $1.78 on the Nasdaq. The views and opinions expressed herein ...

SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

12don MSN

Sage sues Biogen in wake of $469M buyout offer: report

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results